AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed small cell lung cancer * No mixed histology * Extensive stage disease, defined as any of the following: * Metastatic disease outside the chest * Contralateral supraclavicular nodes or contralateral hilar nodes that cannot be included in a single radiation port * Cytologically confirmed malignant pleural effusion * Clinically significant effusions (e.g., symptomatic pleural effusion) must be drained prior to treatment * Previously untreated disease\* OR stable disease, partial response, or complete response ≤ 4 weeks after completion of one course (four 3-week courses) of standard platinum-based chemotherapy * No symptomatic, untreated, or uncontrolled CNS metastases * CNS metastases previously treated with whole brain radiotherapy allowed * ECOG performance status (PS) 0-2 * Life expectancy ≥ 12 weeks * WBC ≥ 3,000/mm³ * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin \> 9.0 g/dL * Total bilirubin \< 1.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 times ULN * ALT and AST ≤ 3 times ULN (≤ 5 times ULN if liver involvement) * Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min * Proteinuria ≤ +1 on two consecutive dipsticks taken no less than 24hours apart * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective protection during and for up to 8 weeks after completion of study therapy * QTc interval ≤ 460 msec * No seizure disorder * No significant traumatic injury ≤ 4 weeks prior to registration * No clinically significant infection * No HIV-positivity * No second primary malignancy, except for carcinoma in situ of the cervix or nonmelanoma skin cancer, unless prior malignancy was diagnosed and treated ≥ 5 years with no subsequent evidence of recurrence * Patients with a history of low grade(Gleason score ≤ 6) localized prostate cancer will be eligible even if diagnosed \< 5 years prior to registration * No concurrent severe and/or uncontrolled medical conditions, including any of the following: * Cardiac arrhythmias * Angina pectoris uncontrolled with medication * Myocardial infarction within the past 3 months * Significant ECG abnormalities * Hypertension, labile hypertension, or history of poor compliance with anti-hypertensive medication * Congestive heart failure within the past 3 months, unless ejection fraction \> 40% * Interstitial pneumonia or extensive, symptomatic interstitial fibrosis of the lung * Poorly controlled diabetes * No history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530 * No condition that impairs the ability to swallow AZD0530 tablets, including any of the following: * Gastrointestinal tract disease resulting in an inability to take oral medication or requiring IV alimentation * Prior surgical procedures affecting absorption of AZD0530 tablets * Active peptic ulcer disease * No serious condition that, in the opinion of the investigator, would compromise the patient's ability to complete the study * At least 4 weeks since prior major surgery (i.e., laparotomy) or open biopsy * At least 2 weeks since prior minor surgery * At least 4 weeks since any prior investigational ancillary therapy (i.e., utilized for a non-FDA-approved indication and in the context of a research investigation) * At least 7 days since prior use of strong inhibitors of CYP3A4 and no concurrent use for up to 7 days after discontinuation of AZD0530 * Prior nonthoracic palliative radiotherapy allowed * Concurrent bisphosphonates for treatment of lytic metastatic bone disease allowed at the discretion of the treating physician * No concurrent prophylactic granulocyte colony-stimulating factor (i.e., G-CSF) * No concurrent products that stimulate thrombopoiesis * No concurrent St. John's wort * No other concurrent chemotherapy, immunotherapy, hormonal therapy,or radiotherapy